These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 16960976)
1. Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents. Proceedings of the Third Cambridge Conference. September 23-24, 2005. Cambridge, Massachusetts, USA. Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4365s-4457s. PubMed ID: 16960976 [No Abstract] [Full Text] [Related]
2. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Lynch TJ; Adjei AA; Bunn PA; Eisen TG; Engelman J; Goss GD; Haber DA; Heymach JV; Jänne PA; Johnson BE; Johnson DH; Lilenbaum RC; Meyerson M; Sandler AB; Sequist LV; Settleman J; Wong KK; Hart CS Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4365s-4371s. PubMed ID: 16857812 [No Abstract] [Full Text] [Related]
3. Two drugs beat back lung tumors. Cancer Discov; 2015 Feb; 5(2):100. PubMed ID: 25656878 [No Abstract] [Full Text] [Related]
4. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Lim SM; Syn NL; Cho BC; Soo RA Cancer Treat Rev; 2018 Apr; 65():1-10. PubMed ID: 29477930 [TBL] [Abstract][Full Text] [Related]
5. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how? Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825 [TBL] [Abstract][Full Text] [Related]
7. [Current usage of molecular targeting drugs]. Sugio K Gan To Kagaku Ryoho; 2010 Aug; 37(8):1459-62. PubMed ID: 20860096 [No Abstract] [Full Text] [Related]
9. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Engelman JA; Cantley LC Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4372s-4376s. PubMed ID: 16857813 [TBL] [Abstract][Full Text] [Related]
10. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
11. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Jänne PA; Johnson BE Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820 [TBL] [Abstract][Full Text] [Related]
12. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. Lynch TJ; Blumenschein GR; Engelman JA; Espinoza-Delgado I; Govindan R; Hanke J; Hanna NH; Heymach JV; Hirsch FR; Janne PA; Lilenbaum RC; Natale RB; Riely GJ; Sequist LV; Shapiro GI; Shaw A; Shepherd FA; Socinski M; Sorensen AG; Wakelee HA; Weitzman A J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S107-12. PubMed ID: 18520291 [TBL] [Abstract][Full Text] [Related]
13. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Politi K; Ayeni D; Lynch T Cancer Cell; 2015 Jun; 27(6):751-3. PubMed ID: 26058074 [TBL] [Abstract][Full Text] [Related]
15. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Rossi A; Pasquale R; Esposito C; Normanno N Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519 [TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755 [TBL] [Abstract][Full Text] [Related]
17. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone. Friedrich MJ J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503 [No Abstract] [Full Text] [Related]
18. [II. Development and Future Prospects of the Third-Generation EGFR-Tyrosine Kinase Inhibitor]. Sakata S; Iwama E; Okamoto I Gan To Kagaku Ryoho; 2015 Aug; 42(8):935-9. PubMed ID: 26353390 [No Abstract] [Full Text] [Related]
19. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Patel JD; Pasche B; Argiris A Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824 [TBL] [Abstract][Full Text] [Related]
20. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Dowell JE; Minna JD Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125 [No Abstract] [Full Text] [Related] [Next] [New Search]